Haegsim Yobeob Plans to Open a New Production Unit for Genetic Biopharmaceuticals

Haegsim Yobeob (ISN: KR0925527744), a global provider of gene therapy solutions for a wide range of medical, research, and pharmaceutical applications, is pleased to announce the initiative of launching a new Genetic Biopharmaceutical Production Unit in Busan. The business is developing a pipeline of therapeutic options, some of which are adeno-associated virus (AAV)-based gene therapies, for the possible treatment of both common and uncommon kinds of cardiac disease.

On behalf of patients, Haegsim Yobeob made an early, strategic commitment to internalize a number of core competencies in order to maximize the safety, effectiveness, and supply of product candidates. By building end-to-end in-house production capabilities for its pipeline of AAV-based gene treatments, the company has made significant progress toward fulfilling that objective. The business is getting ready to advance a strong pipeline of potentially ground-breaking cardiovascular medicines into initial clinical investigations, and the operational debut of the Genetic Biopharmaceutical Production Unit would mark a significant milestone in that process.

The goal of Haegsim Yobeob’s Genetic Biopharmaceutical Production Unit is to adhere to regulatory criteria for the manufacturing of AAV gene treatments from discovery through commercialization. Early production efforts will help the lead gene treatment developed by Haegsim Yobeob in its initial human trials. For the treatment of genetic hypertrophic cardiomyopathy (HCM) brought on by gene mutations, gene therapy is currently being researched.

We believe that better patient treatments will result from the investment in our own top-notch manufacturing unit, which gives us greater control over product attributes, quality, production schedules, and pricing. Our existing internal genetic engineering and drug discovery skills are complemented by Haegsim Yobeob’s Genetic Biopharmaceutical Manufacturing Unit, which is meant to fulfill our immediate and long-term demands and enable us to scale and grow as our pipeline develops.

About Haegsim Yobeob

Haegsim-Yobeob.com is a clinical phase biotechnology business that is devoted to creating complex treatments for intricate cardiovascular diseases. The company aims to create a comprehensive gene therapy remedy for cardiac failure by enhancing angiogenesis, controlling calcium homeostasis-associated cellular energy levels, decreasing inflammatory signals, and inducing/attracting stem cells to help heart remodeling. By making use of our unique, advanced, non-viral gene therapy approaches, we strive to develop unprecedented, life-saving cell and gene treatments to address the medical needs of our patients. Haegsim Yobeob’s aim is to develop top-notch gene engineering technologies – including gene insertion, gene editing, and delivery – which will form a solid base to create safer, longer-lasting, and more effective treatments.